Current treatment options in advanced/recurrent endometrial cancer

This video, led by Prof. Christian Marth, explores the latest treatment strategies for advanced/recurrent endometrial cancer. It highlights the shift from traditional chemotherapy to personalised therapies driven by molecular profiling.

The animated video walks you through a patient case study as you review:

• The role of molecular subtypes in guiding treatment
• Current 1^st line options in patients with non-dMMR advanced/recurrent EC, including immunotherapy, PARP inhibitors, and targeted therapies
• The importance of clear patient communication to support informed decision-making and optimise care

Clinical takeaways

• Molecular classification is crucial not only for prognosis but also for guiding personalised treatment decisions 
• ICI and ChT combination, including with maintenance olaparib, demonstrates PFS benefits and manageable safety in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations 
• Lenvatinib plus pembrolizumab is a viable option not only as 2^nd line therapy but also as 1^st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting
• Shared decision-making, supported by patient education, is essential for optimising treatment outcomes